TY - JOUR
T1 - Leucine-Rich Diet Modulates the Metabolomic and Proteomic Profile of Skeletal Muscle during Cancer Cachexia
AU - Cruz, Bread
AU - Oliveira, André
AU - Viana, Lais Rosa
AU - Lopes-Aguiar, Leisa
AU - Canevarolo, Rafael
AU - Colombera, Maiara Caroline
AU - Valentim, Rafael Rossi
AU - Garcia-Fóssa, Fernanda
AU - de Sousa, Lizandra Maia
AU - Castelucci, Bianca Gazieri
AU - Consonni, Sílvio Roberto
AU - Martins-de-Souza, Daniel
AU - de Jesus, Marcelo Bispo
AU - Russell, Steven Thomas
AU - Gomes-Mardondes, Maria Cristina Cintra
N1 - © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
PY - 2020/7/13
Y1 - 2020/7/13
N2 - Background: Cancer-cachexia induces a variety of metabolic disorders, including skeletal muscle imbalance. Alternative therapy, as nutritional supplementation with leucine, shows a modulatory effect over tumour damage in vivo and in vitro. Method: Adult rats distributed into Control (C), Walker tumour-bearing (W), control fed a leucine-rich diet (L), and tumour-bearing fed a leucine-rich diet (WL) groups had the gastrocnemius muscle metabolomic and proteomic assays performed in parallel to in vitro assays. Results: W group presented an affected muscle metabolomic and proteomic profile mainly related to energy generation and carbohydrates catabolic processes, but leucine-supplemented group (WL) recovered the energy production. In vitro assay showed that cell proliferation, mitochondria number and oxygen consumption were higher under leucine effect than the tumour influence. Muscle proteomics results showed that the main affected cell component was mitochondria, leading to an impacted energy generation, including impairment in proteins of the tricarboxylic cycle and carbohydrates catabolic processes, which were modulated and improved by leucine treatment. Conclusion: In summary, we showed a beneficial effect of leucine upon mitochondria, providing information about the muscle glycolytic pathways used by this amino acid, where it can be associated with the preservation of morphometric parameters and consequent protection against the effects of cachexia.
AB - Background: Cancer-cachexia induces a variety of metabolic disorders, including skeletal muscle imbalance. Alternative therapy, as nutritional supplementation with leucine, shows a modulatory effect over tumour damage in vivo and in vitro. Method: Adult rats distributed into Control (C), Walker tumour-bearing (W), control fed a leucine-rich diet (L), and tumour-bearing fed a leucine-rich diet (WL) groups had the gastrocnemius muscle metabolomic and proteomic assays performed in parallel to in vitro assays. Results: W group presented an affected muscle metabolomic and proteomic profile mainly related to energy generation and carbohydrates catabolic processes, but leucine-supplemented group (WL) recovered the energy production. In vitro assay showed that cell proliferation, mitochondria number and oxygen consumption were higher under leucine effect than the tumour influence. Muscle proteomics results showed that the main affected cell component was mitochondria, leading to an impacted energy generation, including impairment in proteins of the tricarboxylic cycle and carbohydrates catabolic processes, which were modulated and improved by leucine treatment. Conclusion: In summary, we showed a beneficial effect of leucine upon mitochondria, providing information about the muscle glycolytic pathways used by this amino acid, where it can be associated with the preservation of morphometric parameters and consequent protection against the effects of cachexia.
KW - Experimental cachexia
KW - Leucine-rich diet
KW - Metabolomic
KW - Mitochondria dysfunction
KW - Proteomic
KW - Skeletal muscle
UR - https://www.mdpi.com/2072-6694/12/7/1880
UR - http://www.scopus.com/inward/record.url?scp=85087899318&partnerID=8YFLogxK
U2 - 10.3390/cancers12071880
DO - 10.3390/cancers12071880
M3 - Article
C2 - 32668598
SN - 2072-6694
VL - 12
JO - Cancers
JF - Cancers
IS - 7
M1 - 1880
ER -